The Albumin-Globulin Ratio Mediates Progressive Motor Function Decline in Duchenne Muscular Dystrophy

Why It Matters

Identifying AGR as a predictive, modifiable biomarker offers clinicians a tool to stratify risk and explore anti‑inflammatory strategies that could slow DMD progression.

Key Takeaways

• Lower AGR linked to higher Vignos scores in DMD patients.
• AGR predicts fourfold increased risk of ambulatory loss.
• Age‑related decline partially mediated by AGR levels.
• Body weight negatively moderates AGR‑age relationship.
• AGR could serve as therapeutic target in Duchenne management.

Pulse Analysis

Duchenne muscular dystrophy remains a leading cause of pediatric disability, with limited biomarkers to forecast disease trajectory. Systemic inflammation, reflected by the albumin‑globulin ratio, has emerged as a candidate indicator, yet its clinical relevance was unclear. By comparing over 200 DMD patients to healthy peers, researchers established that a reduced AGR correlates with heightened disease severity, underscoring the inflammatory milieu’s role in muscle degeneration.

Statistical modeling in the study highlighted AGR’s predictive power: lower ratios were tied to significantly higher Vignos scores at baseline and follow‑up, and to a hazard ratio of 4.86 for ambulatory loss. Mediation analyses further revealed that AGR accounts for roughly 10 % of the age‑driven functional decline, suggesting it acts as a conduit between aging processes and muscle weakness. Notably, body weight exerted a negative moderating effect, indicating that heavier patients may experience amplified AGR‑related deterioration, a nuance that could refine risk stratification.

Clinically, these insights position AGR as a readily measurable, cost‑effective marker to identify high‑risk DMD patients and monitor therapeutic response. The findings also open avenues for interventions targeting systemic inflammation—such as nutritional optimization or anti‑inflammatory agents—to modulate AGR levels and potentially decelerate functional loss. Future trials should evaluate whether modifying AGR translates into tangible improvements in motor outcomes, thereby enriching the therapeutic arsenal against Duchenne muscular dystrophy.